Simvastatin increases the in vivo activity of the first-line tuberculosis regimen

BACKGROUND: The need to develop new, improved treatments for tuberculosis (TB) remains urgent, and the repurposing of existing drugs represents a possible shortcut to market. Recently, there has been significant interest in host-directed adjuvant therapy to enhance bacillary killing. HMG-CoA reducta...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Skerry, Ciaran, Pinn, Michael L., Bruiners, Natalie, Pine, Richard, Gennaro, Maria L., Karakousis, Petros C.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2014
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184365/
https://ncbi.nlm.nih.gov/pubmed/24855121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dku166
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares